ORIC Pharmaceuticals, Inc. (ORIC) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	—	—	—	—	—
Cost of Revenue	584.0K	1.2M	1.1M	1.0M	—
Gross Profit	(584.0K)	(1.2M)	(1.1M)	(1.0M)	—
Operating Expenses
R&D Expense	122.4M	109.8M	114.1M	85.2M	61.7M
SG&A Expense	33.8M	33.2M	28.8M	25.6M	25.1M
General & Admin Expense	33.8M	33.2M	28.8M	25.6M	25.1M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(584.0K)	(1.2M)	(1.1M)	(1.0M)	5.0M
Total Operating Expenses	155.6M	141.8M	141.8M	109.7M	91.8M
Cost and Expenses	156.1M	143.0M	142.9M	110.8M	91.8M
Operating Income (EBIT)	(156.1M)	(143.0M)	(142.9M)	(110.8M)	(91.8M)
Non-Operating
Interest Income	—	—	—	10.1M	2.6M
Interest Expense	—	—	—	—	2.6M
Net Interest Income	—	—	—	10.1M	—
Other Non-Op Income/Expense	15.8M	13.5M	15.0M	10.1M	2.6M
Non-Operating Income (excl Interest)	(12.0M)	(13.5M)	(15.0M)	(10.1M)	(5.0M)
EBT (Pre-Tax Income)	(140.4M)	(129.5M)	(127.8M)	(100.7M)	(89.1M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(140.4M)	(129.5M)	(127.8M)	(100.7M)	(89.1M)
Earnings from Cont. Ops	(140.4M)	(129.5M)	(127.8M)	(100.7M)	(89.1M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(140.4M)	(129.5M)	(127.8M)	(100.7M)	(89.1M)
Per Share
Basic EPS	($1.35)	($1.47)	($1.83)	($1.96)	($2.25)
Diluted EPS	($1.35)	($1.47)	($1.83)	($1.96)	($2.25)
Revenue Per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Shares
Basic Shares Outstanding	108.0M	87.8M	69.7M	51.5M	39.7M
Diluted Shares Outstanding	108.0M	87.8M	69.7M	51.5M	39.7M
Profitability Metrics
EBITDA	(143.0M)	(128.2M)	(126.7M)	(99.7M)	(85.8M)
D&A	1.1M	1.2M	1.1M	1.0M	966.0K
EBIT	(144.2M)	(129.5M)	(127.8M)	(100.7M)	(86.8M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026